Therapeutics News and Research

RSS

Synthetic biology approach boosts growth of implanted liver tissue

In patients developing end-stage liver disease, the damage has become too severe for the liver's normally extraordinary regenerative capacity to repair or compensate for it. Once this "point of no return" has been reached, the only option is an organ transplant.

17 Apr 2026

Nature-inspired vesicles offer new path for precision medicine therapies

A quiet revolution is underway in modern medicine: Drug development is aiming to move from managing disease to correcting it through RNA and gene-editing therapies.

17 Apr 2026

Scientists find unexpected immune pathways for mRNA cancer vaccines

The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic.

17 Apr 2026

AI-designed peptides break through the outer defenses of MRSA bacteria

A newly-designed AI-powered tool is effective in developing treatments to attack antibiotic-resistant bacteria by breaking down their outer defenses, according to new research from Houston Methodist.

17 Apr 2026

Why AI is becoming a powerful tool in cancer drug discovery

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical translation, with an AI-designed TNIK inhibitor trial serving as an important proof-of-feasibility reference point. It argues that precision oncology could benefit from AI-driven integration of multi-omics, federated learning, and adaptive trial design, but only if validation, fairness, interpretability, and regulatory alignment improve.

16 Apr 2026

New lab-grown organoids accurately mimic pediatric brain tumor biology

Efforts to identify and evaluate next-generation therapeutics for pediatric brain tumors are easily stymied by the quality and availability of laboratory models for research. To address this issue, scientists at St. Jude Children's Research Hospital developed patient-derived tumor organoids and tumor organoid xenografts that accurately reflect the biologic underpinnings of embryonal brain tumors.

16 Apr 2026

Waters debuts industry-first extended-range MALS detector for UHPLC/UPLC, powering rapid characterization of large molecules

Waters Corporation today announced the launch of the Waters omniDAWN™ Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio.

From Waters Corporation 16 Apr 2026

New RNA sequencing method improves rare disease diagnosis

Researchers from Children's Hospital of Philadelphia (CHOP) developed a new RNA sequencing strategy that can reveal how genetic variants disrupt gene function and improve the diagnosis of rare diseases.

15 Apr 2026

Dutch study shows off-label targeted therapies benefit more cancer patients

The largest published prospective evaluation of off-label targeted cancer therapies has shown that more patients could benefit from existing drugs.

15 Apr 2026

Bio-Rad extends range of anti-idiotypic antibodies and anti-Fc mutation antibodies for bioanalysis and drug monitoring

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies, with the introduction of eight antibodies specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isatuximab (Sarclisa), nirsevimab (Beyfortus), and tremelimumab (Imjudo), and released a recombinant monoclonal anti-biotherapeutic antibody specific to dulaglutide (Trulicity).

From Bio-Rad Laboratories 15 Apr 2026

ProImmune collaborates with The University of Texas Medical Branch to advance infectious disease research

ProImmune, Ltd., a global leader in immunological reagents and services, today announced a collaboration with The University of Texas Medical Branch (UTMB) Galveston National Laboratory (GNL), a high-containment, infectious disease research facility, to develop innovative tools for studying high-consequence emerging and endemic infectious diseases.

From ProImmune Ltd. 15 Apr 2026

VALANX Biotech establishes Scientific Advisory Board to advance ADC therapeutics

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug discovery, today announced the formation of its Scientific Advisory Board (SAB), appointing John Lambert as Chair, with Morris Rosenberg and Peter de Waele serving alongside.

From VALANX Biotech 15 Apr 2026

Ultrasensitive assay uncovers hidden burden of tuberculosis disease

Researchers at Boston University have discovered an unexpectedly high prevalence of Mycobacterium tuberculosis DNA (TB DNA) in patients hospitalized in Boston, suggesting that tuberculosis disease may be significantly underdiagnosed in the United States.

14 Apr 2026

Experimental drug shows survival benefit in pancreatic cancer trial

Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis.

14 Apr 2026

Alzheimer's risk gene APOE4 impacts bone health in females

Scientists at the Buck Institute for Research on Aging, along with collaborators at UC San Francisco, have discovered that APOE4, the most common genetic risk factor for Alzheimer's disease, causes bone quality deficits specifically in female mice, through a mechanism that is invisible to standard imaging and can emerge as early as midlife.

13 Apr 2026

NTU Singapore and partners develop new inhaled treatment for severe lung infections

Nanyang Technological University, Singapore (NTU Singapore) is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology company Lipigon Pharmaceuticals AB to develop a new inhaled treatment aimed at helping patients recover faster from severe lung infections.

13 Apr 2026

Mutations in RNU2-2 gene linked to neurodevelopmental disorders

A seminal study from researchers at the Icahn School of Medicine at Mount Sinai and their collaborators in the United Kingdom, Belgium, Spain, the Netherlands, and Iceland has uncovered a new genetic cause of neurodevelopmental disorders (NDDs).

11 Apr 2026

Damon Runyon supports young scientists driving cancer research innovation

The Damon Runyon Cancer Research Foundation has named 13 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.

11 Apr 2026

Pseudogene lncRNAs regulate cancer stem cell behavior and signaling

Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, and resistance to therapy due to their innate capacity for self-renewal and differentiation.

11 Apr 2026

EV-RNAs show promise for IBD diagnosis and treatment

A research team led by Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, has published a comprehensive review in ExRNA that sorts out the diverse roles of extracellular vesicle-associated RNAs (EV-RNAs) in the development and progression of inflammatory bowel disease (IBD).

10 Apr 2026